Attenuated afferent inhibition correlated with impaired gait performance in Parkinson’s disease patients with freezing of gait
2024

Afferent Inhibition and Gait Performance in Parkinson's Disease

Sample size: 71 publication 10 minutes Evidence: moderate

Author Information

Author(s): Wen Puyuan, Zhu Hong, Liu Zaichao, Chang Amin, Chen Xianwen

Primary Institution: The First Affiliated Hospital of Anhui Medical University, Hefei, China

Hypothesis

The study investigates the correlation between short-latency and long-latency afferent inhibition and gait performance in Parkinson's disease patients with freezing of gait.

Conclusion

The study found that reduced short-latency and long-latency afferent inhibition in Parkinson's disease patients with freezing of gait is associated with impaired gait performance.

Supporting Evidence

  • Short-latency afferent inhibition was significantly reduced in both FOG subgroups compared to healthy controls.
  • Long-latency afferent inhibition was also decreased in both FOG subgroups, with significant reductions in levodopa unresponsive patients compared to non-FOG patients.
  • FOG patients exhibited poorer gait performance compared to healthy controls and non-FOG patients.
  • The reduction of afferent inhibition was correlated with impaired gait spatiotemporal parameters.

Takeaway

People with Parkinson's disease who have trouble walking also have problems with how their brain processes movement signals.

Methodology

The study included 71 participants divided into four groups: levodopa responsive-FOG, levodopa unresponsive-FOG, non-FOG PD patients, and healthy controls, with assessments of gait performance and afferent inhibition using transcranial magnetic stimulation.

Potential Biases

Potential bias due to subjective classification of freezing of gait and variability in dopaminergic treatment among participants.

Limitations

The sample size is small, and the study was conducted in the 'ON' state of medication, which may influence results.

Participant Demographics

Participants included 25 levodopa responsive-FOG patients, 15 levodopa unresponsive-FOG patients, 28 non-FOG PD patients, and 22 healthy controls.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fnagi.2024.1458005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication